# REGENEREX PHARMA, INC.

REGENEREX PHARMA, INC. is a company headquartered in Las Vegas, NV, United States.

## Company overview

- **Legal name:** REGENEREX PHARMA, INC.
- **Former names in filing history:** PEPTIDE TECHNOLOGIES, INC. (2011-10-13 to 2021-12-22); Eternelle Skincare Products Inc. (2017-06-23 to 2018-02-08); CREENERGY Corp (2010-06-29 to 2011-10-06); ONLINE ORIGINALS, INC (2006-04-18 to 2010-07-19)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Las Vegas, NV, United States
- **Incorporated in:** NV
- **Fiscal year end:** December 31
- **SEC CIK:** 0001357878

## About

REGENEREX PHARMA, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001357878, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-06-30, it reported net income of USD -2,527,041; total assets of USD 1,263,236 for the fiscal period ended 2025-03-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2025-03-31)

- **Net income:** -$2.5M (USD -2,527,041)
- **Total assets:** $1.3M (USD 1,263,236)
- **Cash and equivalents:** $653,025 (USD 653,025)
- **Operating cash flow:** -$1.6M (USD -1,625,351)

### FY2023 (period ended 2024-03-31)

- **Net income:** -$3.5M (USD -3,543,827)
- **Total assets:** $766,680 (USD 766,680)
- **Cash and equivalents:** $372 (USD 372)
- **Operating cash flow:** -$457,548 (USD -457,548)

### FY2023 (period ended 2023-03-31)

- **Net income:** -$137,330 (USD -137,330)
- **Total assets:** $6,539 (USD 6,539)
- **Cash and equivalents:** $1,135 (USD 1,135)
- **Operating cash flow:** -$76,164 (USD -76,164)

### FY2022 (period ended 2022-03-31)

- **Net income:** -$195,591 (USD -195,591)
- **Total assets:** $15,322 (USD 15,322)
- **Cash and equivalents:** $2,640 (USD 2,640)
- **Operating cash flow:** -$69,922 (USD -69,922)

## Recent SEC filings

- Form 8-K — filed 2026-09-04 — period 2026-09-04 — CURRENT REPORT
- Form 8-K — filed 2026-09-01 — period 2026-09-01 — CURRENT REPORT
- Form 8-K — filed 2026-06-22 — period 2026-06-19 — CURRENT REPORT
- Form 8-K — filed 2026-06-11 — period 2026-06-11 — CURRENT REPORT
- Form 8-K — filed 2026-05-06 — period 2026-05-06 — CURRENT REPORT
- Form 8-K — filed 2026-04-02 — period 2026-03-31 — CURRENT REPORT
- Form 10-Q — filed 2025-11-17 — period 2025-09-30 — QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2025
- Form 8-K — filed 2025-11-12 — period 2025-11-11 — CURRENT REPORT
- Form 8-K — filed 2025-09-03 — period 2025-09-03 — CURRENT REPORT
- Form 10-Q — filed 2025-08-14 — period 2025-06-30 — QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2025
- Form 8-K — filed 2025-07-31 — period 2025-07-31 — CURRENT REPORT
- Form 10-K — filed 2025-06-30 — period 2025-03-31 — ANNUAL REPORT FOR THE FISCAL YEAR ENDED MARCH 31, 2025

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/regenerex-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology